Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation

Vittoria Massafra*, Alexandra Milona*, Harmjan R. Vos, Boudewijn M. T. Burgering, Saskia W. C. van Mil*

Center for Molecular Medicine, UMC Utrecht, Utrecht, The Netherlands

*These authors contributed equally to this work.
*S.W.C.vanMil@umcutrecht.nl

Abstract

Fibroblast growth factor 19 (FGF19) is a gut-derived peptide hormone that is produced following activation of Farnesoid X Receptor (FXR). FGF19 is secreted and signals to the liver, where it contributes to the homeostasis of bile acid (BA), lipid and carbohydrate metabolism. FGF19 is a promising therapeutic target for the metabolic syndrome and cholestatic diseases, but enthusiasm for its use has been tempered by FGF19-mediated induction of proliferation and hepatocellular carcinoma. To inform future rational design of FGF19-variants, we have conducted temporal quantitative proteomic and gene expression analyses to identify FGF19-targets related to metabolism and proliferation. Mice were fasted for 16 hours, and injected with human FGF19 (1 mg/kg body weight) or vehicle. Liver protein extracts (containing “light” lysine) were mixed 1:1 with a spike-in protein extract from 13C6-lysine metabolically labelled mouse liver (containing “heavy” lysine) and analysed by LC-MS/MS. Our analyses provide a resource of FGF19 target proteins in the liver. 189 proteins were upregulated (≥ 1.5 folds) and 73 proteins were downregulated (≤ -1.5 folds) by FGF19. FGF19 treatment decreased the expression of proteins involved in fatty acid (FA) synthesis, i.e., Fabp5, Scd1, and Acsl3 and increased the expression of Acox1, involved in FA oxidation. As expected, FGF19 increased the expression of proteins known to drive proliferation (i.e., Tgfbi, Vcam1, Anxa2 and Hdlbp). Importantly, many of the FGF19 targets (i.e., Pdk4, Apoa4, Fas and Stat3) have a dual function in both metabolism and cell proliferation. Therefore, our findings challenge the development of FGF19-variants that fully uncouple metabolic benefit from mitogenic potential.

Introduction

Fibroblast growth factors (FGFs) are secreted signalling proteins with a wide range of functions in metabolic regulation, cell growth and differentiation, angiogenesis, embryonic development, as well as wound healing and repair [1]. Endocrine FGFs, i.e. FGF19, FGF21 and FGF23 constitute a subfamily of FGFs secreted in the circulation with roles in bile acid (BA),
glucose and lipid metabolism (FGF19), metabolic adaptation during fasting (FGF21), and modulation of vitamin D and phosphate homeostasis (FGF23) [2].

FGF19 (FGF15 in rodents) is a postprandial enterokine induced by the nuclear hormone receptor Farnesoid X Receptor (FXR; NR1H4) upon activation by BAs [3]. FGF19 signals from intestine to liver via binding to FGFR4/β-klotho receptor complex to repress the gene encoding cholesterol 7α-hydroxylase (CYP7A1), which catalyses the first and rate-limiting step in the classical BA synthetic pathway [4]. In addition, FGF19 prevents lipid and glucose accumulation in the liver by inducing fatty acid oxidation and decreasing expression of acetyl coenzyme A carboxylase 2 (Acc2) involved in FA synthesis [5, 6]. Furthermore, FGF19 inhibits lipogenesis by counteracting the insulin-induced increase of sterol regulatory element-binding protein-1c (SREBP-1c) expression, a key transcriptional activator of genes involved in lipogenesis [7, 8]. FGF19 regulation of glucose metabolism involves stimulation of glycogen synthesis [9] and inhibition of gluconeogenesis via inactivation of cAMP regulatory element-binding protein (CREB) and subsequent decrease in proliferator-activated receptor γ coactivator-1α (PGC-1α) [10].

The beneficial impact of FGF19 on lipid, glucose and BA homeostasis raise the possibility to pursue FGF19 as a therapeutic target for diabetes, metabolic syndrome and cholestatic liver diseases. However, the development of FGF19-based therapeutics is hampered by the mitogenic potential of FGF19 and its subsequent tumorigenic implications. FGF19-transgenic mice display increased hepatocyte proliferation at 2–4 months of age and develop hepatocellular carcinoma (HCC) at 10–12 months [11]. In concurrence with this, tumour progression in HCC patients is associated with increased FGF19 expression [12], and FGF19 gene has been shown to be a driver gene for HCC [13]. In an effort to eliminate the tumorigenic activity of FGF19 without compromising its beneficial metabolic effects, variants of FGF19 with diminished proliferative potential have been engineered, for example by eliminating the binding site to FGFR4 [14–16]. Although these results are very promising, caution should be taken since changes in metabolism have been recognized to play a driver role in oncogenesis with the ability to control both genetic and epigenetic events in cells (reviewed in [17]). It is therefore possible that the effects of FGF19 on proliferation and tumorigenesis may also be induced by its effects on metabolism.

Therefore, a comprehensive understanding of the FGF19 signalling cascade, together with mechanistic insights into the effects of FGF19 on metabolism and proliferation, are essential for the design of an FGF19-based therapeutic. Here we investigate the proteome-wide changes induced in mice upon administration of human recombinant FGF19. By using an untargeted proteomics approach, we expand the knowledge on FGF19-mediated protein expression changes and reveal that FGF19 indeed acts as a regulator of BA, lipid, glucose, amino acid metabolism and as a signalling molecule inducing expression of proliferative and tumorigenic proteins. We also show by pathway analyses that many of the proteins regulated by FGF19 function both in metabolism and proliferation, emphasizing that FGF19-mediated effects on proliferation may not so easily be eliminated without also affecting the beneficial effects on metabolism.

Materials and methods

Animal experiments

Wt C5Bl/6 male mice (8 weeks) were housed in groups, with enriched bedding, were fed standard chow ad libitum. They were fasted for 16 hours prior to treatment to ensure low endogenous FGF15 signalling. Mice received a single intraperitoneal dose of human recombinant FGF19 (1 mg/kg body weight, R&D Systems, Minneapolis, U.S.) in 0.1% saline solution or
vehicle. Mice were terminated after 0 min, 15 min, 1 h, 2 h, 4 h or 12 h and liver tissue was snap frozen for RNA and protein analyses. Mice were euthanized by decapitation. This method of euthanasia was selected based on scientific need as it is the quickest, minimizes the distress and anxiety experienced by the animal, prevents stress induced pathways induced by CO₂ inhalation and prevents glucose and other metabolic changes induced by anaesthesia. Injections and decapitations were performed by experienced staff to prevent animal discomfort. The study protocol was approved by the University Medical Center Utrecht Ethical Committee for Animal Experimentation.

**Mass spectrometry sample preparation**

Liver protein extracts were generated by homogenizing 50 mg liver tissue in PBS and subsequent lysis in lysis buffer (1% NP40, 150 mM NaCl, 1 mM DTT, 50 mM Tris pH 8.0, Roche Proteinase inhibitors). Next, 100 μg protein extract from Wt or FXR-/- mice ('light') were mixed 1:1 with a spike-in protein extract generated from ¹³C₆-lysine metabolically labelled mouse liver ('heavy') (Silantes, Munich, Germany). Proteins were denatured in urea, alkylated with iodoacetamide (Sigma, S Louis, MO, U.S.) and digested with 1 μg of trypsin (Promega, Fitchburg, WI, U.S.) using a Filtered Aided Sample Purification Protocol (FASP [18]). After trypsinization, peptides were fractionated based on their pH using Strong Anionic Exchange Chromatography and finally desalted and acidified on a C-18 cartridge (3M, St. Paul, MN, U. S.). C18-stage tips were activated with methanol, washed with buffer containing 0.5% formic acid in 80% ACN (buffer B) and then with 0.5% formic acid (buffer A). After loading of the digested sample, stage-tips were washed with buffer A and peptides were eluted with buffer B, dried in a SpeedVac, and dissolved in buffer A.

**Mass spectrometry and data analysis**

Peptides were separated in a 30 cm column (75 μm ID fused silica capillary with emitter tip (New Objective)) packed with 3 μm aquapur gold C-18 material (dr Maisch, Ammerbuch-Entringen, Germany) using a 140 minute gradient (7% to 80% ACN, 0.1% FA), and delivered by an easy-nLC 1000 (Thermo, Waltham, MA, U.S.). Peptides were electro-sprayed directly into an Orbitrap Fusion Tribrid Mass Spectrometer (Thermo Scientific) and analysed in Top Speed data-dependent mode with the resolution of the full scan set at 24000 and an intensity threshold of 5000 ions. Most intense ions were isolated by the quadrupole and fragmented with a HCD collision energy of 30%. The maximum injection time of the iontrap was set to 35 milliseconds.

Raw files were analysed with the Maxquant software version 1.5.1.0. [19] For identification, the mouse Uniprot 2012 was searched with both the peptide as well as the protein false discovery rate set to 1%. The SILAC quantification algorithm was used in combination with the ‘match between runs’ tool (option set at two minutes), the IBAQ and the LFQ algorithm [20]. Proteins identified were filtered for reverse hits, decoy hits and standard contaminants by using the Perseus software 1.5.1.6 [21]. The liver proteomic profile of three mice per group was determined. Light/heavy normalized ratios were used to quantify protein expression and were further processed for comparative analysis of differential expression among the experimental groups. Proteins were filtered to have more than 1 unique or razor peptide and at least two valid values per group. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [22] partner repository with the dataset identifier PXD005659. Analysed data are presented in the S1 File. Pathway analysis was performed using Ingenuity Pathway Analysis Program (IPA; Ingenuity Systems, Redwood City, CA, U. S.).
Gene expression analyses
RNA was isolated from liver using TRIzol reagent (Invitrogen, Waltham, MA, U.S.). cDNA was generated from 1 μg of total RNA using SuperScript II Reverse Transcriptase (Invitrogen). qRT-PCR analysis was performed using SYBR green PCR master mix (Roche, Basel, Switzerland) and analysed on a MyIQ real time PCR cycler (BioRad, Hercules, California, U.S.). Data are presented as relative expression normalized to Gapdh gene expression. Primer sequences are listed in S1 Table.

Western blotting
Liver tissue was homogenized in Lysis Buffer (1% NP40, 50 mM Tris HCl pH 7.4, 1 mM EDTA, 150 mM NaCl, 5 mM NaF, 0.25% sodium deoxycholate, 2 mM NaVO₃ and protease inhibitors) using a Tissue Lyzer II (Qiagen, Venlo, The Netherlands) and protein concentration was assessed (BCA assay kit, Thermo Scientific). Western blots were probed with antibodies against Stat3 (Cat. Nr. 9139, Cell Signalling Technology, Danvers, MA, U.S.) and phospho-Stat3 (Tyr 705) (Cat. Nr. 9131, Cell Signalling Technology). α-Tubulin (Sigma), antibody was used as a loading control.

Statistics
For the proteomic analysis a T-test was applied to determine significant differential expressed proteins between the groups (p-value < 0.05). Statistical significance of pathway enrichment and upstream regulator analyses were assessed by using IPA software. Only pathways significantly enriched (setting p < 0.01) are shown. For the upstream regulator analysis, p-value measures whether there is a statistically significant overlap between the dataset genes and the genes that are regulated by a transcription factor/hormone/compound, based on the published data included in Ingenuity database. It is calculated using Fisher’s Exact Test, and significance was attributed to p-values < 0.01.

Results
FGF19-mediated regulation of liver protein expression resolved by quantitative proteomics
In order to characterize the metabolic and proliferative effects elicited by FGF19, we quantified protein expression changes in liver extracts from wild type mice treated with FGF19 or vehicle for 12h. Prior to FGF19 injection, mice were fasted for 16 hours, in order to reduce enterohpetic BA circulation and subsequent endogenous FGF15 signalling. Liver protein extracts (containing ‘light’ lysine) were mixed 1:1 with a spike-in protein extract from 13C₆-lysine metabolically labelled mouse liver (containing ‘heavy’ lysine) and analysed by LC-MS/MS (Fig 1A). Spike-in efficiency, indicating the quality of the heavy signal as internal standard, was assessed as frequency of proteins ranked based on their log2 heavy/light normalized ratio (Fig 1B). More than 80% of proteins from the mouse liver exposed to vehicle had a heavy/light ratio close to 1, indicating a substantial equality in protein composition of the liver from our mice and the ‘heavy’ liver tissue commercially available, thereby supporting the suitability of the heavy labelled liver as internal standard for the light samples. In a scatterplot comparing FGF19- to vehicle-treated mice, light/heavy protein ratios distribute in a cloud along the diagonal with a Pearson correlation $R^2 = 0.937$ (S1 Fig).

Our proteomic analysis identified 6511 proteins, of which 5459 were identified with two or more razor or unique peptides, were not reverse hits, decoy hits or standard contaminants. All proteins were identified with a minimum false discovery rate < 0.01 (Q-value, [23]). 3 mice
FGF19 and in vivo liver proteomics

(A) FGF19 or Veh

16h fasting

0h 12h

Sacrifice

LC-MS/MS

Mass spec sample preparation

Protein extraction

Mixing 1:1 ‘light’ and ‘heavy’

13C-6-Lys spike-in

(B) Spike-in efficiency

protein frequency

log H/L Veh normalized ratio

-6  -5  -4  -3  -2  -1  0  1  2  3  4

(C) Protein ranking FGF19 (12h)/Veh (12h)

Proteins

75 110 145

(D) FGF19 (12h) / Veh (12h)

Gene name

Protein ID

Protein name

Fold change

Fabp5
Q9F816
Fatty acid-binding protein, epidermal
-1.59

Cyp7a1
Q68505
Cholesterol 7-alpha-monoxygenase
-2.53

Hsl1X1a
P43275
Histone H3.2
-2.06

Ces2c
Q9WS60
Acyl-CoA hydroxylase
-1.97

Scl1
Q9FZ32
Acyl-CoA desaturase 1; Acyl-CoA desaturase 2
-1.88

Cbd4
Q9FQD2
Chromodomain-helicase-DNA-binding protein 4
-1.82

Cyp2c70
Q9WS64
Cytochrome P450 2C70
-1.73

Ggcx
Q9NW72
Vitamin K-dependent gamma-carboxylase
-1.66

F9
P12594
Coagulation factor IX
-1.01

Uqcrh
P99028
Cytochrome b-c1 complex subunit 6, mitochondrial
-1.56

Cyp7b1
Q9F991
25-hydroxycholesterol 7-alpha-hydroxylase
-1.56

Hox11hc
P12584
Histone H3.2
-1.50

Sic2b23
Q60Q53
Calcium-binding mitochondrial carrier protein ScaMC-3
-1.50

Gene name

Protein ID

Protein name

Fold change

Kiaa0020
Q88K59
Purinergic domain-containing protein KIAA0020
1.39

Hao2
Q9VYQ2
Hydroxysteroid oxidase 2
2.65

Colba3
Q9VWQ3
Protein Colba3
2.23

Nog14
Q6R3H1
Nuclear protein 14
2.23

Tgfb1
Q3UHJ2
Transforming growth factor-beta induced protein 3
2.09

Sun2
Q9VWJ5
SUN domain-containing protein 2
1.78

Abcb1
P12547
Multidrug resistance protein 1
1.77

Col14a1
B72H47
Collagen alpha-1(XV) chain
1.76

Vcam1
Q9JFN1
Vascular cell adhesion protein 1
1.76

Aldr
Q9Q7B8
Gamma-isoeductin
1.75

Nop56
Q9D6G1
Nuclear protein 56
1.74

Web75
Q9J8E1
WD repeat-containing protein 75
1.72

Herpdl
Q9J230
Heterogeneous nuclear ribonucleoprotein-D-like
1.68

Fup
Q9CFQ0
RNA-binding protein FUS
1.67

Myctb
Q7TQD7
Unconventional myosin-ib
1.67

Herpap1
Q9E8F8
Heterogeneous nuclear ribonucleoprotein A1
1.65

Hnnox1
P15901
Heme oxygenase 1
1.65

Herpap2b1
F5U5D6
Heterogeneous nuclear ribonucleoproteins A2/B1
1.64

Dlcs21
Q9H5K5
Nuclear RNA helicase 2
1.62

Vcl
Q64727
Vinculin
1.60

Mal3
Q9K310
Malatin-3
1.59

Tnleb
Q3V452
Protein Tnleb
1.58

Hnph1
Q37377
Heterogeneous nuclear ribonucleoprotein-H
1.57

Snpa
Q6J218
U1 small nuclear ribonucleoprotein A
1.57

Sklc2b2
Q9C0S3
Supercil mounting/tiling activity 2-like 2
1.56

Smu1
Q3UK77
WD40 repeat-containing protein SMU1
1.55

Sic2a2
Q8Y5P7
Large neutral amino acids transporter small subunit 3
1.55

Herpap3
Q8R8Q5
Heterogeneous nuclear ribonucleoprotein-A3
1.55

Catp
P17934
Carnitine O-acetyltransferase
1.54

Slc2a9
Q1I3F0
Protein Slc2a9
1.54

Ik
Q9Q28E
Protein Ik
1.53

Sun52
Q9DBX3
Sushi domain-containing protein 2
1.52

Slc9a14
Q7SN73
Zinctransporter ZIP14
1.52

Elav1
P73072
ELAV-like protein 1
1.52

Khdbs1
Q6T479
KH domain-containing, RNA-binding, signal transcription-associated protein 1
1.50

Myo7
Q69T7N
Myoflinin
1.50
per group were included in the analysis and 2453 proteins had at least 2 valid values in each group. No imputation of missing values by normal distribution was performed. FGF19 treatment for 12 hours resulted in upregulation (1.5 fold) of 189 proteins and downregulation (-1.5 fold) of 73 proteins compared to vehicle treatment for 12 hours (Fig 1C).

Significant expression differences upon 12h FGF19 treatment are depicted in a Volcano Plot (Fig 1D). Proteins involved in cell proliferation (e.g. transforming growth factor beta-induced protein ig-h3, Tgfbi; myoferlin), metabolism (e.g. Hao2, Crat2, Abcb1), anchoring to nuclear membrane (Sun2) and nucleolar proteins (Nop14, Nop56) were among the most upregulated proteins 12h after FGF19 injection. Proteins involved in BA synthesis (Cyp7a1, Cyp7b1), lipid metabolism (Fabp5, Scd1, Ces2c), oxidative phosphorylation (Sclc2a23, Uqcrh) and other metabolic processes (Ggcx, Cyp2c70) were significantly downregulated (Fig 1D).

Together, the in vivo proteome dataset identifies FGF19 as a regulator of metabolism and proliferation, and next to yet unknown targets, identifies Cyp7A1 amongst the highest regulated genes, as was previously reported [4].

FGF19 modulates expression of proteins involved in metabolism and cell survival

For a comprehensive understanding of FGF19 function, we performed IPA to understand which pathways were significantly enriched 12h after FGF19 treatment in comparison with the vehicle control. To have a very stringent cut-off of FGF19 targets, we did not perform imputation of missing values in each triplicate, as it is sometimes done. Consequently, the calculated number of significantly changed proteins in Fig 1 was too small for pathway analyses. We have therefore included proteins with fold change ≥ 1.3 (FGF19/vehicle) in our next analyses. FGF19 treatment yielded changes in wide ranging metabolic processes, including BA, cholesterol, lipid, glucose, amino acid, nucleotide, RNA metabolism and inflammation (Fig 2A). The pathway ‘BA synthesis’ was given a negative activation z-score, associated with decreased activity of this pathway, concurrent with the previously described role for FGF19 as enterohepatic negative regulator of BA synthesis [4]. The functional categories that can be summarized under ‘cell survival’ were enriched in the proteome dataset of the FGF19 stimulated livers, with an induction of pro-proliferative proteins and a negative activation score for proteins involved in cell death. In addition, pathways involved in tumorigenesis, such as ‘invasion’ and ‘tumour growth’ were significantly enriched and activated. Therefore, the changes observed in the liver proteomic profile of the mice receiving FGF19 confirm the role of FGF19 as a metabolic regulator, but also substantiate the concern about the tumorigenicity of FGF19 administration.

We subsequently aimed to investigate which proteins underlie FGF19-mediated regulation of metabolism and cell survival/cancer in the IPAs. Together, 183 proteins changed upon FGF19 treatment that were involved in different aspects of metabolism (e.g. Acot2, Acox1 and Acsl3) and 267 in cell survival/cancer (Col6a3, Tgfbi, Vcam1, Anxa2 and Hdlbp) (Fig 2B). However, of these proteins, 127 proteins were included in both metabolism and cell survival/
cancer pathways (Fig 2B). This overlap includes Pdk4, Apoa4, Apoe, Vim, Gtpbp4, Fas (upregulated) and Stat3 (downregulated). Although the IPA algorithm is based on counting associations in published data and is therefore limited, these results suggest that separation between FGF19 proliferative and metabolic functions may be more complex than was previously anticipated.

Evaluation of changes in gene expression involved in metabolic and proliferative function of FGF19

Since FGF19 regulated the expression of the above described proteins after 12 hour treatment, we addressed whether transcriptional regulation of metabolic and proliferative genes by FGF19 precedes the up/downregulation observed at protein level. We injected mice with FGF19 and harvested the livers at t = 0, 15 min, 1h, 4h and 12h after a 16h pre-fasting period, in order to analyse FGF19 function without the confounding effect of endogenous FGF15 signalling (Fig 3A). We took along a group which received only the vehicle and was terminated after 12h, to be able to correct for differences due to prolonged starvation. Expression of the BA synthesis enzyme Cyp7a1 decreased upon FGF19 treatment, as expected (Fig 3B). The signal transducer and activator of transcription 3 (Stat3) had been previously reported to exhibit an increased phosphorylation and activation in response to FGF19, with subsequent effects both on proliferation and inhibition of FA synthesis [7, 16]. Here we show that FGF19 increases gene expression of Stat3 (Fig 3B). The mRNA expression of the proliferative markers Egfr and c-Fos (not detected at protein level in our proteome dataset) peaked within 4h after FGF19 administration, in line with a previous study [14].

We next investigated whether protein expression changes of newly identified FGF19 targets listed in Fig 2B reflect also mRNA expression regulation. Indeed, FA oxidation enzyme Acox1 mRNA expression increased and peaked 1h after FGF19 injection, whereas FA synthesis enzyme long-chain-fatty-acid-CoA ligase 3 (Acsl3) was decreased in FGF19-treated mice compared to vehicle controls (Fig 3B). Apolipoprotein Apoa4 mRNA expression increased and peaked 12h after FGF19 treatment, whereas Apoe mRNA expression was increased up to 4h after injection and was back to normal after 12h. mRNA expression of tumor necrosis factor receptor superfamily member 6 (Fas) and nucleolar GTP-binding protein 1 (Gtpbp4), implicated in both metabolism and cell survival, were increased 12h after FGF19 treatment, thus preceding the increase observed at protein level at 12h. mRNA expression of vigilin (Hdlbp), and calcium-dependent phospholipid binding protein Annexin A2 (Anxa2), both involved in cell proliferation, were increased 12h after FGF19 treatment. The change in mRNA expression of the aforementioned novel targets concur with the up/down regulation observed at protein level (Fig 2B). In contrast, Fabp5, implicated in lipid metabolism, and Tgfbi, implicated in cell survival, were not regulated at mRNA level by FGF19 (data not shown), despite their protein expression being significantly changed 12h after FGF19 injection (Fig 1D). Therefore, these gene expression studies confirm most novel metabolic and proliferative targets of FGF19, but also indicate that not all protein expression changes observed upon 12h FGF19 treatment, are preceded by a consistent change at mRNA level.
In view of the high relevance of the Stat3 protein for liver homeostasis, we further analysed protein levels of Stat3 at 15 min, 1h, 2h, 4h and 12h after FGF19 treatment by Western Blotting. Stat3 protein levels were upregulated significantly at 15 min and 4 hours after FGF19 treatment (Fig 4A), in line with the gene expression data (Fig 3B). Protein levels were not significantly changed at 1, 2 and 12 hours after FGF19 treatment. Variability among the mice at these time points and lower sensitivity of the western blotting compared to the mass-spectrometry quantification may underlie the difference in the results obtained with western blot and the proteome, where we detected a small decrease in Stat3 at 12h (Fig 2B). Of note, phosphorylation of Stat3 at Tyr705 was increased at 15 min, 1h and 2h after FGF19 treatment (Fig 4B). Since phosphorylation prevents Stat3 degradation via the ubiquitin-proteasome pathway [24] and promotes nucleus translocation and activation of Stat proteins [25], it may be that the increase in Stat3 protein 15 minutes after FGF19 treatment reflects an increase in protein stability, rather than a direct transcriptional effect.

FGF19 elicits expression changes in target genes of tumorigenic regulators

Next, we applied the Ingenuity upstream regulator analysis to the liver proteome dataset, which allows prediction of upstream regulators associated with the detected protein expression changes. We distinguished regulators of metabolism and proliferation (Fig 5). The analysis correctly identifies FGF19 and cholic acid ( bile acid) as upstream regulators of the protein expression changes observed in our proteome dataset. In addition, the analysis identifies as upstream regulators the known FGF19 targets Egfr, c-Fos and the Stat3, the latter being activated by FGF19 and here reported to be regulated also at expression level. Furthermore, overlap with nuclear receptor signalling (PPARα, PPARγ, HNF4α, SHP, and LXR, PGC1α, and RIP140), transcription (NFE2L2, HNF1α, FOXA2) and insulin and glucagon was identified. In accordance with FGF19-dependent regulation of lipid metabolism, also arachidonic acid, fatty acid, and cholesterol were identified as possible upstream regulators.

Interestingly, Ingenuity analysis suggests that FGF19 may have a similar activation program as that triggered by growth factors (Vegf and Egf), oncogenes (Myc, Kras) and Tgfβ signalling (Tgfb1, Smad3, Tgfb2, Tgfb1; Fig 4A, right panel). Tgfβ is considered both a tumor suppressor and pro-oncogenic factor [26]. FGF19 injection changed the expression of many proteins known to be regulated by Tgfβ, including Col6a3, Tgfb1, vascular cell adhesion protein 1 (Vcam1), heme oxygenase 1 (Hmox1), vinculin (Vcl) and vimentin (Vim) (Table 1). Taken together, these analyses identify similarities between FGF19 and known regulators of tumorigenesis and proliferation, indicating that FGF19 may have similar targets or mediates its effects via these regulators.

Discussion

The elucidation of the molecular basis for FGF19 function is of great interest for the design of an FGF19-based therapeutic deprived of its tumorigenic potential, but retaining its beneficial effects on BA, lipid and glucose homeostasis. Investigation of the molecular mechanisms underlying FGF19 function has so far relied on targeted approaches, by addressing whether FGF19 induces the activity of key signalling proteins known to be involved in metabolism and
In the present study, we have taken an unbiased approach to determine FGF19 targets that underlie metabolic and proliferative effects. We deployed untargeted quantitative proteomics to generate a comprehensive view of FGF19 function in mouse liver. Both analysis of top regulated proteins and pathway enrichment studies in our proteome dataset support the involvement of FGF19 signalling in a wide range of processes, including BA, cholesterol, lipid, glucose, amino acid, nucleotide, and RNA metabolism, as well as cell survival and proliferation.

Fig 4. FGF19 regulates Stat3 expression and phosphorylation at Tyr705. Western blot analyses of Stat3 protein (A) and phospho-Stat3 (Tyr705) (B) at 0h, 15 min, 1h, 2h and 12h after FGF19 treatment. Quantification for Stat3 is shown as relative protein signal normalized to tubulin. Data are expressed as mean ± SD. Each lane represents one mouse liver.

doi:10.1371/journal.pone.0171185.g004
tumorigenesis. As well as decreasing the expression of BA synthesis enzyme Cyp7a1, FGF19 decreases the protein expression of Acsl3, and Scd1, implicated in FA synthesis and Fabp5, involved in FA transport. In addition, protein expression of Acox1, involved in FA oxidation and the apolipoproteins Apoe and Apoa4 are upregulated by FGF19. In almost all cases, the regulation of protein expression was preceded by a change in mRNA level. Our results on FGF19-dependent activation of growth-related pathways in the liver are in agreement with previous reports, showing that Fgf15\(-/-\) mice develop less hepatocellular carcinoma compared to Fgf15\(+/-\) littermates [55], and display impaired liver regeneration [56].

An important mechanism for FGF19 induction of cell proliferation is the phosphorylation and subsequent activation of Stat3 [16]. Besides, FGF19 proliferative function requires the binding to FGFR4, since FGF19-induced increase in proliferative markers is attenuated in the liver of Fgfr4 knockout mice [14]. On the basis of this information, variants of FGF19 were engineered with reduced proliferative potential. The FGF19 variant M70 harbours 3 amino acid substitutions and a 5-amino acid deletion in the N-terminus [15]. As a result, M70 fails to activate the proliferative factor Stat3 and does not promote hepatocellular carcinoma formation in mice, while retaining the ability to maintain BA homeostasis and even to ameliorate

**Fig 5.** FGF19 elicits expression changes in target genes of tumorigenic regulators. (A) Ingenuity upstream regulator analysis applied to protein changes observed upon FGF19 treatment for 12h. Prediction of upstream regulators is based on the overlap between the dataset proteins and the genes that are regulated by a transcription factor/hormone/compound, based on the knowledge included in Ingenuity database (overlap p-value <0.01). Green bars, upstream regulators with positive activation z-score; grey bars, upstream regulators with negative activation z-score.

doi:10.1371/journal.pone.0171185.g005
BDL- and ANIT-induced cholestasis in mice [16, 57]. Our work shows that FGF19 increases not only Stat3 phosphorylation status (and thereby its stability) at early time points, but also Stat3 expression after treatment for 4 hours. Therefore, it would be relevant to test FGF19 variants for their ability to regulate Stat3 expression, other than activity. Another FGF19 variant (FGF19v), which does not bind and activate Fgfr4, is also devoid of proliferative effects [14]. Fgfr4 seems not be required for improvement of glucose tolerance by FGF19, therefore FGF19v may effectively control glucose homeostasis [14]. FGFR4 is essential for FGF19-dependent repression of Cyp7a1 and therefore FGF19v exhibits impaired regulation of BA metabolism [14]. These FGF19 variants deprived of tumorigenic effects are very promising from a therapeutic perspective, however, their use in clinic is challenged by the limited information available regarding FGF19 metabolic and proliferative targets. For example, although in ob/ob mice serum glucose levels were significantly decreased in mice treated with both FGF19 and M70 (24 weeks), triglycerides, cholesterol and LDL and HDL were markedly increased compared to untreated ob/ob mice [16]. This indicates that caution should be taken to interpret FGF19 actions on metabolism as beneficial under all circumstances.

It is also unclear to what extent it is mechanistically possible to discriminate FGF19 metabolic and proliferative function, as changes in metabolism are known to drive tumorigenic events [17]. Our proteome analysis reveals that FGF19 upregulates the protein expression of Tgfb1, Col6a3, Vcam1, Anxa2 and Hdlbp, that are implicated in cell survival. In the case of Hdlbp and Anxa2, but not of Tgfb1, we could show that FGF19 treatment for 12 hours determined a concurrent increase in mRNA expression. Also the mRNA expression of the proliferative markers Egfr and c-Fos was upregulated by FGF19 in our experiment, as previously described [14]. We cannot exclude that some of the observed FGF19 effects could be indirect and dependent on the induced expression of other growth factors. For example, we show that FGF19 activates a gene expression program similar to that induced by Egf. Indeed, it has been previously shown that FGF19 increases expression of Egf receptor ligands such as amphiregulin, which mediate part of the proliferative effects of FGF19 [58]. Importantly, 127 of the proteins regulated by FGF19 were annotated in both metabolism and cell survival categories in the IPA analysis, e.g. Fas, Gtpbp4 and Stat3. This number is probably an underestimation of

| TGFB target in the proteome dataset | FC upon FGF19 treatment | p-value | IPA Gene regulation by TGFB | Reference |
|------------------------------------|-------------------------|--------|-----------------------------|-----------|
| COL6A3                             | 2.23                    | 0.001  | Up                          | [27, 28]  |
| TGFBI                              | 2.09                    | 0.011  | Up                          | [29–31]   |
| VCAM1                              | 1.76                    | 0.040  | Down                        | [32, 33]  |
| HMOX1                              | 1.65                    | 0.023  | Up                          | [34–38]   |
| VCL                                | 1.60                    | 0.032  | Up                          | [39]      |
| VIM                                | 1.49                    | 0.032  | Up                          | [31, 40–43]|
| BSG                                | 1.44                    | 0.033  | Up                          | [44]      |
| ITGA1                              | 1.44                    | 0.032  | Up                          | [45, 46]  |
| GNAI2                              | 1.43                    | 0.034  | Down                        | [47]      |
| ABCA1                              | 1.40                    | 0.006  | Up                          | [48–50]   |
| JUP                                | 1.37                    | 0.024  | Down                        | [46, 51, 52]|
| DES                                 | 1.34                    | 0.006  | Up                          | [53]      |
| PTGS1                              | 1.33                    | 0.024  | Up                          | [29, 54]  |

Top list of proteins changed in our proteome dataset that are predicted as TGFB1 targets by Ingenuity upstream regulator analysis. The fold change observed in our dataset upon FGF19 treatment and the direction of gene regulation (up/down) by TGFB1 inferred from literature are reported.

doi:10.1371/journal.pone.0171185.t001
the interplay between metabolism and cell survival pathways, since this analysis relies on publicly available data. The close interlink between metabolism and proliferation is not surprising, since metabolic reprogramming is essential for cell survival. As an example, pyruvate dehydrogenase kinase 4 (Pdk4), which is upregulated by FGF19 in our experiment (Fig 2B), provides an advantage during the proliferative state of the cell by driving the accumulation of glycolytic intermediates [59].

To overcome the limits of the intimate link between metabolic and proliferative mechanisms in designing therapeutic FGF19 variants, analysis of key tumorigenic FGF19 targets with limited or no involvement in metabolism should be addressed for dissociation between metabolic and proliferative functions. Indeed, the M70-mediated adverse effects on cholesterol and triglyceride concentrations [16] are likely due to Stat3 being the transcriptional repressor of Srebp1c [7], which activates cholesterol and fatty acid biosynthesis. Therefore blocking of Stat3 activity prevents proliferation, but also dysregulates cholesterol metabolism. Our study identifies Anxa2 and Tgfbi as possible tumorigenic FGF19 targets, without no apparent function in BA, cholesterol or lipid metabolism. The proliferative activity of Anxa2 has been associated with tumour progression, since increased Anxa2 expression correlates with a more invasive phenotype and induces proliferation and invasion signalling in human breast cancer cells [60–62]. Similarly, Tgfbi, which is a protein involved in cell adhesion and cell-collagen interactions [63], has also been implicated in tumorigenesis [64]. Intriguingly, expression of Tgfb and its target gene Ctgf was previously shown to be decreased in Fgf15−/− mice compared to Fgf15+/+ littermates [55]. In light of these observations, it would be informative to investigate whether these proteins critically mediate FGF19-dependent tumorigenesis. And if so, whether FGF19 variants blocking the activity of these targets are devoid of tumorigenic effects and have preserved metabolic activity.

In conclusion, our untargeted liver proteome analyses show that FGF19-mediated regulation of metabolism and proliferation is complex, and involves protein expression changes relating to BAs, glucose, lipid, amino acids, together with inflammatory, proliferative and tumorigenic processes. Future studies should address the exact mechanisms by which these proteins are regulated by FGF19, to understand whether the effects on carcinogenesis can be dissociated from beneficial effects on metabolism.

Supporting information
S1 Fig. FGF19-mediated regulation of liver protein expression resolved by quantitative proteomics. (A) Scatterplot distribution of FGF19-induced protein expression changes expressed as log2 light/heavy normalized ratios. Pearson correlation between protein expressions in FGF19-treated mice and protein expressions in Veh-treated mice is shown. (TIF)

S1 File. Proteomic analysis of livers from mice treated with FGF19 or vehicle for 12 hours. List of proteins identified in the liver and their expression values expressed as light/heavy normalized ratios. Median of three mice/group is calculated and fold change FGF19/vehicle is shown. (XLSX)

S1 Table. Mouse qRT-PCR primers. (DOCX)

Acknowledgments
We thank Ellen Willemsen, Noortje Ijssennagger, Ingrid Bijsmans and Margreet Vonk Noordegraaf for technical assistance and José Miguel Ramos Pittol for critical discussion.
Author contributions

Conceptualization: AM VM SWCvM.

Formal analysis: VM.

Funding acquisition: SWCvM HRV.

Investigation: VM AM HRV.

Methodology: VM HRV AM.

Project administration: SWCvM.

Resources: HRV AM.

Supervision: BMTB.

Validation: VM.

Visualization: VM.

Writing – original draft: VM SWCvM.

Writing – review & editing: AM BMTB.

References

1. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8(3):235–53. PubMed Central PMCID: PMCPMC3684054. doi: 10.1038/nrd2792 PMID: 19247306

2. Degirolamo C, Sabha C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016; 15(1):51–69. doi: 10.1038/nrd.2015.9 PMID: 26567701

3. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003; 17(13):1581–91. PubMed Central PMCID: PMCPMC196131. doi: 10.1101/gad.1083503 PMID: 12815072

4. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005; 2(4):217–25. doi: 10.1016/j.cmet.2005.09.001 PMID: 16213224

5. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004; 145(6):2594–603. doi: 10.1210/en.2003-1671 PMID: 14976145

6. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology. 2002; 143(5):1741–7. doi: 10.1210/endo.143.5.8850 PMID: 11956156

7. Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem. 2009; 284(15):10023–33. PubMed Central PMCID: PMCPMC2665057. doi: 10.1074/jbc.M808818200 PMID: 19233843

8. Miyata M, Sakaizawa Y, Matsuzawa H, Yoshinari K, Yamazoe Y. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice. Biol Pharm Bull. 2011; 34(12):1885–9. PMID: 22130247

9. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011; 331(6024):1621–4. PubMed Central PMCID: PMCPMC3076083. doi: 10.1126/science.1198363 PMID: 21436455

10. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab. 2011; 13(6):729–38. PubMed Central PMCID: PMCPMC3131185. doi: 10.1016/j.cmet.2011.03.019 PMID: 21641554

11. Nicholas K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.
12. Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012; 12:56. PubMed Central PMCID: PMCPMC3293719. doi: 10.1186/1471-2407-12-56 PMID: 22309595

13. Sawey ET, Chanron M, Cai C, Wu G, Zhang J, Zender L, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell. 2011; 19(3):347–58. PubMed Central PMCID: PMCPMC3060878. doi: 10.1016/j.ccr.2011.01.040 PMID: 21397858

14. Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One. 2011; 6(3):e17868. PubMed Central PMCID: PMCPMC3060878. doi: 10.1371/journal.pone.0017868 PMID: 21437243

15. Wu X, Ge H, Lemon B, Vonderfecht S, Baribault H, Weiszmann J, et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci U S A. 2010; 107(32):14158–63. PubMed Central PMCID: PMCPMC2922594. doi: 10.1073/pnas.1009427107 PMID: 20660733

16. Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu JY, et al. Separating Tumorigenicity from Bile Acid Regulator Activity for Endocrine Hormone FGF19. Cancer Res. 2014; 74(12):3306–16. doi: 10.1158/0008-5472.CAN-14-0208 PMID: 24728076

17. Hirschey MD, DeBerardinis RJ, Diehl AM, Drew JE, Frezza C, Green MF, et al. Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol. 2015; 35 Suppl:S129–50. PubMed Central PMCID: PMCPMC4656121. doi: 10.1016/j.semcancer.2015.10.002 PMID: 26454069

18. Wisniewski JR, Zougman A, Mann M. Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. J Proteome Res. 2009; 8(12):5674–8. doi: 10.1021/pr900748n PMID: 19848406

19. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008; 26(12):1367–72. doi: 10.1038/nbt.1511 PMID: 19029910

20. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011; 473(7347):337–42. doi: 10.1038/nature10098 PMID: 21593866

21. Cox J, Mann M. 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. BMC Bioinformatics. 2012; 13 Suppl 16:S12. PubMed Central PMCID: PMCPMC3489530.

22. Vizcaino JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016; 44(D1):D447–56. PubMed Central PMCID: PMCPMC4702828. doi: 10.1093/nar/gkv1145 PMID: 26527252

23. Kall L, Storey JD, MacCoss MJ, Noble WS. Posterior error probabilities and false discovery rates: two sides of the same coin. J Proteome Res. 2008; 7(1):40–4. doi: 10.1021/pr070393d PMID: 18052118

24. Murase S. Signal transducer and activator of transcription 3 (STAT3) degradation by proteasome controls a developmental switch in neurotrophin dependence. J Biol Chem. 2013; 288(28):20151–61. PubMed Central PMCID: PMCPMC3711283. doi: 10.1074/jbc.M113.470583 PMID: 23733189

25. Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264(5164):1415–21. PMID: 8197455

26. Jakowlew SB. Transforming growth factor-beta and cancer in metastasis. Cancer Metastasis Rev. 2006; 25(3):435–57. doi: 10.1007/s10555-006-9006-2 PMID: 16951986

27. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem. 2001; 276(20):17058–62. doi: 10.1074/jbc.M100754200 PMID: 11279127

28. Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, et al. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res. 2005; 7(6):R1058–79. PubMed Central PMCID: PMCPMC1410754. doi: 10.1186/bcr1343 PMID: 16457687

29. Chambers RC, Leoni P, Kaminski N, Laurent GJ, Heller RA. Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol. 2003; 162(2):533–46. PubMed Central PMCID: PMCPMC1851161. PMID: 12547711
30. Miyazaki YJ, Hamada J, Tada M, Furuuchi K, Takahashi Y, Kondo S, et al. HOXD3 enhances motility and invasiveness through the TGF-beta-dependent and -independent pathways in A549 cells. Oncogene. 2002; 21(5):798–808. doi: 10.1086/320512 PMID: 11850808

31. Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, et al. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem. 2008; 283(30):21065–73. PubMed Central PMCID: PMCPMC2475688. doi: 10.1074/jbc.M802786200 PMID: 18499657

32. Knittel T, Dinter C, Kobold D, Neubauer K, Mehdie M, Eichhorst S, et al. Expression and regulation of cell adhesion molecules by hepatic stellate cells (HSC) of rat liver: involvement of HSC in recruitment of inflammatory cells during hepatic tissue repair. Am J Pathol. 1999; 154(1):153–67. PubMed Central PMCID: PMCPMC1853435. PMID: 9916930

33. Zhang Z, Ma J, Yao K, Yin J. Alpha-melanoctye stimulating hormone suppresses the proliferation of human tenon’s capsule fibroblast proliferation induced by transforming growth factor beta 1. Mol Biol (Mosk). 2012; 46(4):628–33.

34. Hili-Kapturczak N, Truong L, Thamilselvan V, Visner GA, Agarwal A. Smad7-dependent regulation of heme oxygenase-1 by transforming growth factor-beta1 in human renal epithelial cells. J Biol Chem. 2000; 275(52):40904–9. doi: 10.1074/jbc.M006621200 PMID: 11018038

35. Kutty RK, Nagineni CN, Kutty G, Hooks JJ, Chader GJ, Wiggert B. Increased expression of heme oxy-lin CC, Chiang LL, Lin CH, Shih CH, Hsu MJ, et al. Transfor ming growth factor-beta1 stimu-lates heme oxygenase-1 expression via the PI3K/Akt and NF-kappaB pathways in human lung epithelial cells. Eur J Pharmacol. 2007; 560(2–3):101–9. doi: 10.1016/j.ejphar.2007.01.025 PMID: 17307160

36. Pellacani A, Wiesel P, Sharma A, Foster LC, Huggins GS, Yet SF, et al. Induction of heme oxygenase-1 during endotoxemia is downregulated by transforming growth factor-beta1. Circ Res. 1998; 83(4):396–403. PMID: 9721886

37. Traylor A, Hock T, Hili-Kapturczak N. Specificity protein 1 and Smad-dependent regulation of human heme oxygenase-1 gene by transforming growth factor-beta1 in renal epithelial cells. Am J Physiol Renal Physiol. 2007; 293(3):F885–94. doi: 10.1152/ajprenal.00519.2006 PMID: 17567933

38. Shi-wen X, Stanton LA, Kennedy L, Pala D, Chen Y, Howat SL, et al. CCN2 is necessary for adhesive gene. 2002; 21(5):798–808. doi: 10.1038/sj.onc.1205126 PMID: 11850808

39. Traylor A, Hock T, Hill-Kapturczak N. Specificity protein 1 and Smad-dependent regulation of human heme oxygenase-1 gene by transforming growth factor-beta1 in renal epithelial cells. Am J Physiol Renal Physiol. 2007; 293(3):F885–94. doi: 10.1152/ajprenal.00519.2006 PMID: 17567933

40. Grabias BM, Konstantopoulo K. Epithelial-mesenchymal transition and fibrosis are mutually exclusive responses in shear-activated proximal tubular epithelial cells. FASEB J. 2012; 26(10):4131–41. PubMed Central PMCID: PMCPMC3448778. doi: 10.1096/fj.12-207324 PMID: 22744866

41. Lian N, Lin T, Liu W, Wang W, Li L, Sun S, et al. Transforming growth factor beta suppresses osteoblast differentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and Sp1 family members. Biochim Biophys Acta. 2007; 1773(3):427–39. PubMed Central PMCID: PMCPMC1855268. doi: 10.1016/j.bbamcr.2006.11.017 PMID: 17270292

42. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. 2002; 61(5):1714–28. doi: 10.1046/j.1523-1755.2002.00333.x PMID: 11967021

43. Wu Y, Zhang X, Salmon M, Lin X, Zehner ZE. TGFbeta1 regulation of vimentin gene expression during differentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and Sp1 family members. Biochim Biophys Acta. 2007; 1773(3):427–39. PubMed Central PMCID: PMCPMC1855268. doi: 10.1016/j.bbamcr.2006.11.017 PMID: 17270292

44. Wu J, Ru NY, Zhang Y, Li Y, Wei D, Ren Z, et al. HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-beta signaling and is transcriptionally regulated by Slug. Oncogene. 2011; 30(43):4410–27. doi: 10.1038/onc.2011.149 PMID: 21532623

45. Cerdeira AS, Rajakumar A, Royle CM, Lo A, Husain Z, Thadhani RI, et al. Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J Immunol. 2013; 190(8):3939–48. PubMed Central PMCID: PMCPMC3742368. doi: 10.4049/jimmunol.1202582 PMID: 23487420

46. Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology. 2005; 146(3):1097–118. doi: 10.1210/en.2004-1377 PMID: 15604209

47. Hamby ME, Coppola G, Ao Y, Geschwind DH, Khakh BS, Sofroniew MV. Inflammatory mediators alter the astrocyte transcriptome and calcium signaling elicited by multiple G-protein-coupled receptors. J Neurosci. 2012; 32(42):14489–510. PubMed Central PMCID: PMCPMC3518872. doi: 10.1523/JNEUROSCI.1256-12.2012 PMID: 23077035
48. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM, et al. Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol. 2001; 21(12):2011–8. PMID: 11742878

49. Carter CJ. Convergence of genes implicated in Alzheimer’s disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int. 2007; 50(1):12–38. doi: 10.1016/j.neuint.2006.07.007 PMID: 16973241

50. Hu YW, Wang Q, Ma X, Li XX, Liu XH, Xiao J, et al. TGF-beta1 up-regulates expression of ABCA1, ABCG1 and SR-BI through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. J Atheroscler Thromb. 2010; 17(5):493–502. PMID: 20057170

51. Ilyas M, Efstathiou JA, Straub J, Kim HC, Bodmer WF. Transforming growth factor beta stimulation of colorectal cancer cell lines: type II receptor bypass and changes in adhesion molecule expression. Proc Natl Acad Sci U S A. 1999; 96(6):3087–91. PubMed Central PMCID: PMCPMC15899. PMID: 10077641

52. Weeks BH, He W, Olson KL, Wang XJ. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. Cancer Res. 2001; 61(20):7435–43. PMID: 11606377

53. Popova AP, Bozyk PD, Goldsmith AM, Linn MJ, Lei J, Bentley JK, et al. Autocrine production of TGF-beta1 promotes myofibroblastic differentiation of neonatal lung mesenchymal stem cells. Am J Physiol Lung Cell Mol Physiol. 2010; 298(6):L735–43. PubMed Central PMCID: PMCPMC2886615. doi: 10.1152/ajplung.00347.2009 PMID: 20190033

54. Pilbeam C, Rao Y, Voznesensky O, Kawaguchi H, Alander C, Raissz L, et al. Transforming growth factor-beta1 regulation of prostaglandin G/H synthase-2 expression in osteoblastic MC3T3-E1 cells. Endocrinology. 1997; 138(11):4672–82. doi: 10.1210/endo.138.11.9348193

55. Uriarte I, Latasa MU, Carotti S, Fernandez-Barrena MG, Garcia-Iri goyen O, Elizalde M, et al. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer. 2015; 136(10):2469–75. doi: 10.1002/ijc.29287 PMID: 25346390

56. Uriarte I, Fernandez-Barrena MG, Monte MJ, Latasa MU, Chang HC, Carotti S, et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut. 2013; 62(6):899–910. doi: 10.1136/gutjnl-2012-302945 PMID: 23292666

57. Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med. 2014; 6(247):247ra100. doi: 10.1126/scitranslmed.3009098 PMID: 25080475

58. Latasa MU, Salis F, Urtasun R, Garcia-Iri goyen O, Elizalde M, Uriarte I, et al. Regulation of amphiregulin gene expression by beta-catenin signaling in human hepatocellular carcinoma cells: a novel cross-talk between FGF19 and the EGFR system. PLoS One. 2012; 7(12):e52711. PubMed Central PMCID: PMCPMC3527604. doi: 10.1371/journal.pone.0052711 PMID: 23285165

59. Xie Y, Wang H, Cheng X, Wu Y, Cao L, Wu M, et al. Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming. Sci Rep. 2016; 6:18751. PubMed Central PMCID: PMCPMC4700422. doi: 10.1038/srep18751 PMID: 26728993

60. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol. 2006; 81(2):146–56. doi: 10.1016/j.yexmp.2006.03.003 PMID: 16634892

61. Wu B, Zhang F, Yu M, Zhao P, Ji W, Zhang H, et al. Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells. Cell Prolif. 2012; 45(3):189–98. doi: 10.1111/j.1365-2184.2012.00820.x PMID: 22452352

62. Zhang F, Zhang L, Zhang B, Wei X, Yang Y, Qi RZ, et al. Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res. 2009; 8(11):5041–7. doi: 10.1021/pr900461c PMID: 19764771

63. Skonier J, Bennett K, Rothwell V, Kosows ki S, Plowman G, Wallace P, et al. beta ig-H3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol. 1994; 13(6):571–84. doi: 10.1089/dna.1994.13.571 PMID: 8024701

64. Han B, Cai H, Chen Y, Hu B, Luo H, Wu Y, et al. The role of TGFBI (betaig-H3) in gastrointestinal tract tumorigenesis. Mol Cancer. 2015; 14:64. PubMed Central PMCID: PMCPMC4435624. doi: 10.1186/s12943-015-0335-z PMID: 25889002